期刊
JOURNAL OF NEURO-ONCOLOGY
卷 109, 期 1, 页码 45-52出版社
SPRINGER
DOI: 10.1007/s11060-012-0878-4
关键词
Temozolomide; Glioblastoma cancer stem cell; MGMT; Temozolomide rechallenge
资金
- Bavarian Research Foundation
- START Program (RWTH Aachen, Medical School)
- NGFNplus BTN (subproject 7A) [01GS0887]
- NGFNplus BTN (subproject 7b) [01GS0887]
The effectiveness of temozolomide (TMZ) dosing schemes and the rechallenge of recurrent glioblastoma (GBM) with TMZ are controversial. We therefore compared the efficacy of different TMZ dosing schemes against GBM cancer stem cell (CSC) lines in vitro. In O-6-methyl-guanidine-methyl-transferase (MGMT)-negative CSC lines, all schedules (1 day on/27 days off, 5 days on/23 days off, 7 days on/7 days off, 21 days on/7 days off, continuous low-dose TMZ) depleted clonogenic cells. In TMZ-resistant CSC lines, the 7 days on/7 days off scheme showed higher toxicity as compared with the other schemes. However, clinically feasible concentrations remained ineffective in highly resistant CSC lines. In addition, none of the schedules induced long-term depletion of clonogenic cells even at the highest concentrations (up to 250 mu M). After sublethal TMZ treatment for 5 days, TMZ rechallenge of recovering CSC lines remained effective. Our data advocate CSC lines as in vitro model to address clinical questions. Using this model, our data suggest the effectiveness of TMZ in MGMT-negative CSC lines and support the concept of TMZ rechallenge. The 7 days on/7 days off scheme consistently showed the best activity of all schedules in TMZ-resistant CSC lines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据